Last update May 10, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Ketotifen Fumarate in other languages or writings:
Ketotifen Fumarate belongs to these groups or families:
|Tmax||2 - 4||hours|
|T½||12 (7 - 27)||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
1st-generation-antihistamine and piperidine-type drug with a minimal sedative effect.
Indicated on prophylaxis of asthma, rhinitis (oral administration) and conjunctivitis (administrated as eye drops).
At latest update relevant published data on excretion into breast milk were not found.
Pharmacokinetic data (large volume of distribution and moderately high molecular weight) make it unlikely that significant amounts of milk would pass through breastmilk.
Plasma levels following ophthalmic administration are undetectable (AEMPS 2011).
It is a medicine authorized for use in infants from 6 months of age on.
It does not influence prolactin levels (Dolecek 1984).
Expert authors consider antihistamines compatible with breastfeeding (So 2010).
Until more published data on this drug related to breastfeeding is available, a safer and known alternative should be preferred during the neonatal period and in case of prematurity.
Ophthalmic administration is safe while breastfeeding.